We are live on ! Find out more
APTO

Aptose Biosciences

Delisted

APTO was delisted on the 1st of April, 2025.

23 hedge funds and large institutions have $1.33M invested in Aptose Biosciences in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,929% more capital inflows, than outflows

Capital inflows: $271K | Capital outflows: $6.73K

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

15% more funds holding

Funds holding: 20 → 23 (+3)

2.89% more ownership

Funds ownership: 14.96% → 17.84% (+2.9%)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

Holders
23
Holders Change
+3
Holders Change %
+15%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

APTO Hedge Fund Activity: Q3 2024 in Review

23 of the 6,991 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences (APTO) for Q3 2024, worth a combined $1.33M — down 35% from $2.06M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new APTO positions and 1 closed out — a net gain of 3 holders — while 3 added to existing stakes and 3 trimmed.

The largest buyer was Armistice Capital, adding an estimated $88.8K. The largest seller was TD Waterhouse Canada, cutting an estimated $3.49K.

  • 23 institutional investors held Aptose Biosciences (APTO) as of Q3 2024, up from 20 in Q2 2024.
  • Funds reported $1.33M of Aptose Biosciences stock for Q3 2024, down 35% quarter-over-quarter.
  • 4 funds opened new Aptose Biosciences positions in Q3 2024 and 1 closed out, a net change of +3 holders.
  • The largest Aptose Biosciences buyer in Q3 2024 was Armistice Capital, an estimated $88.8K added.
  • The largest Aptose Biosciences seller in Q3 2024 was TD Waterhouse Canada, an estimated $3.49K sold.

Based on aggregated 13F filings for Q3 2024.